Gene Symbol: DPM3
Full Name: Dolichol-Phosphate Mannosyltransferase Subunit 3
Chromosomal Location: 1q22
NCBI Gene ID: 54344
OMIM: 605066
Ensembl ID: ENSG00000133030
UniProt: Q9BXS5
The DPM3 gene encodes the third subunit of the dolichol-phosphate mannose (DPM) synthase complex, which is essential for protein N-glycosylation and glycolipid biosynthesis . DPM3 plays a crucial role in maintaining the proper function of the DPM complex, which consists of DPM1 (catalytic subunit), DPM2 (regulatory subunit), and DPM3 (scaffold subunit) .
The DPM synthase complex catalyzes the synthesis of dolichol-phosphate mannose (DPM), a critical donor substrate for:
- N-linked Protein Glycosylation: Transfer of mannose to nascent polypeptides in the endoplasmic reticulum
- Glycolipid Biosynthesis: Synthesis of glycosylphosphatidylinositol (GPI) anchors
- C-mannosylation: Rare type of protein glycosylation
Proper glycosylation is essential for neuronal function:
- Synaptic Proteins: Many synaptic receptors and adhesion molecules require proper glycosylation
- Ion Channel Function: Glycosylation affects ion channel trafficking and function
- Neuronal Development: Glycosylation patterns influence neuronal migration and connectivity
DPM3 and the glycosylation pathway have been implicated in Alzheimer's disease:
- APP Processing: Glycosylation affects amyloid precursor protein (APP) processing and amyloid-beta production
- Tau Glycosylation: Abnormal glycosylation patterns have been observed in tauopathies
- Synaptic Glycoproteins: Disrupted glycosylation of synaptic proteins may contribute to synaptic loss
- ER Stress: Impaired glycosylation can trigger unfolded protein response (UPR)
- Alpha-Synuclein Glycosylation: Glycosylation patterns may affect alpha-synuclein aggregation and toxicity
- Dopaminergic Neuron Vulnerability: Glycosylation defects may contribute to dopaminergic neuron susceptibility
- ER Homeostasis: Disrupted protein quality control mechanisms
DPM3 mutations cause Congenital Disorder of Glycosylation Type Ie (CDG-Ie), characterized by:
- Neurological Impairment: Developmental delay, intellectual disability, ataxia
- Seizures: Epileptic episodes in affected individuals
- Muscular Issues: Hypotonia, muscular dystrophy-like features
- Cardiomyopathy: Some patients develop cardiac complications
DPM3 is ubiquitously expressed with highest levels in:
- Brain: Particularly in neurons of the cerebral cortex and hippocampus
- Muscle: Skeletal muscle and cardiac tissue
- Liver: High expression in hepatocytes
- ER-rich cells: Cells with extensive endoplasmic reticulum
Targeting the glycosylation pathway may have therapeutic potential:
- Chaperone Therapy: Small molecules that enhance DPM complex function
- Gene Therapy: AAV-mediated DPM3 delivery for CDG patients
- ER Stress Modulators: Reducing UPR burden in glycosylation defects
- DPM3 mutations cause autosomal recessive CDG-Ie
- Polymorphisms may affect glycosylation efficiency
- Gene-dosage effects in neurodegenerative disease
DPM3 dysfunction has clinical relevance for:
- CDG Diagnosis: Genetic testing for DPM3 mutations
- Therapeutic Monitoring: Assessing glycosylation efficiency
- Biomarker Development: Glycosylation patterns as disease markers